Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans

[1]  G. Frost,et al.  Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. , 2001, American journal of physiology. Endocrinology and metabolism.

[2]  J. Holst,et al.  Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. , 2000, Diabetes.

[3]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[4]  P. MacDonald,et al.  Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. , 1999, Diabetes.

[5]  C Cobelli,et al.  Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake. , 1998, Diabetes.

[6]  A. Ryan,et al.  Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. , 1998, The Journal of clinical endocrinology and metabolism.

[7]  W. Malaisse,et al.  Preserved GLP-I Effects on Glycogen Synthase a Activity and Glucose Metabolism in Isolated Hepatocytes and Skeletal Muscle From Diabetic Rats , 1997, Diabetes.

[8]  J. Holst,et al.  Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. , 1997, Acta physiologica Scandinavica.

[9]  T. Murakami,et al.  Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long-Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. , 1997, Metabolism: clinical and experimental.

[10]  S. Bloom,et al.  Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus , 1997, European journal of clinical investigation.

[11]  M. Byrne,et al.  Human Studies with Glucagon‐like‐peptide‐1: Potential of the Gut Hormone for Clinical Use , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[12]  Y. Matsuzawa,et al.  Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. , 1996, Biochimica et biophysica acta.

[13]  J. Holst,et al.  Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.

[14]  J. Holst,et al.  The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones , 1996, Diabetes.

[15]  I. Valverde,et al.  Glucagon-like peptide-1 binding to rat skeletal muscle , 1995, Peptides.

[16]  I. Valverde,et al.  Glucagon-like peptide-1 binding to rat hepatic membranes. , 1995, The Journal of endocrinology.

[17]  P. Zabel,et al.  Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM , 1995, Diabetes.

[18]  I. Valverde,et al.  Potent glycogenic effect of GLP-1(7–36)amide in rat skeletal muscle , 1994, Diabetologia.

[19]  J. Egan,et al.  Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. , 1994, Endocrinology.

[20]  J. Holst,et al.  Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM , 1994, Diabetes Care.

[21]  I. Valverde,et al.  Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. , 1993, The Journal of clinical endocrinology and metabolism.

[22]  R. Rizza,et al.  Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans. , 1993, The Journal of clinical investigation.

[23]  Shaoping Deng,et al.  Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.

[24]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[25]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[26]  P. Andrews,et al.  Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. , 1990, The Journal of biological chemistry.

[27]  G. Weir,et al.  Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas , 1989, Diabetes.

[28]  L. Mandarino,et al.  Dose-response characteristics for effects of insulin on production and utilization of glucose in man. , 1981, The American journal of physiology.

[29]  B. Göke,et al.  Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic. , 1999, Metabolism: clinical and experimental.

[30]  Jie Zhou,et al.  Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations , 1999, Diabetologia.

[31]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[32]  W. Malaisse,et al.  Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats. , 1998, Endocrinology.